natgillin/translations-raw huggingface dataset:
responsive to the fit quality falling within the predetermined threshold range, determine an updated atlas estimate using the GAM parameters and the atlas parameters based on a target set of covariates. The system of claim 4, wherein the one or more hardware processors are further configured by machine-readable instructions to: 
gdje se ako kvaliteta pristajanja upada ispod zadanog praga, parametre registriranja zanemaruje, ili ako kvaliteta pristajanja ulazi u raspon praga, parametre registriranja se upotrebljava za izračunavanje GAM parametara; i određivanje nadopunjene procjene za atlas uz upotrebu GAM parametara i parametara atlasa na osnovi ciljanog skupa kovarijabli koji odgovara na kvalitetu pristajanja koja ulazi u zadani raspon praga.
Salt according to claim 2 or 3, wherein Z1 is selected from the group consisting of 1-((diphenylmethyl)piperazine; 
Sol prema zahtjevu 2 ili 3, naznačena time, da Z1 je odabran iz skupine koju čine:
for use in preventing weight gain or promoting weight loss; 
(a) uporabu u prevenciji dobivanja prekomjerne težine ili u poticanju smanjivanja težine;
The pharmaceutical composition of claim 8 or 9 for a use as defined in claim 8 or 9, wherein the compound of formula (1) is administered intravenously in an amount of 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 7, gdje se farmaceutska kompozicija treba administrirati intravenski u količini od:
The antibody molecule composition according to any one of claims 19 to 24 wherein the antibody is selected from the group consisting of antibodies against ganglioside GD3, antibodies against human interleukin-5 receptor alpha-chain, antibodies against HER2, antibodies against CC chemokine receptor 4, antibodies against CD20, antibodies against CD22, antibodies against neuroblastoma, antibodies against MUC1, antibodies against epidermal growth factor receptor; in particular an antibody selected from the group consisting of Pankomab, Muromomab, Daclizumab, Basiliximab, Abciximab, Rituximab, Herceptin, Gemtuzumab, Alemtuzumab, Ibritumomab, Cetuximab, Bevacizumab, Tositumomab, Pavlizumab, Infliximab, Eculizumab, Epratuzumab, Omalizumab, Efalizumab, Adalimumab, OKT3, anti-CC chemokine receptor 4 antibody KM2160, and anti-neuroblastoma antibody chCE7. 
Pripravak s molekulom protutijela u skladu s bilo kojim od patentnih zahtjeva 19 do 24, naznačen time što se protutijelo bira iz skupine koju čine protutijela protiv gangliozida GD3, protutijela protiv a-lanca receptora ljudskog interleukina-5, protutijela protiv HER2, protutijela protiv receptora 4 kemokina CC, protutijela protiv CD20, protutijela protiv CD22, protutijela protiv neuroblastoma, protutijela protiv MUCI, protutijela protiv receptora čimbenika rasta epiderme; osobito protutijelo koje se bira iz skupine koju čine Pankomab, Muromomab, Daklizumab, Baziliksimab, Abciksimab, Rituksimab, Herceptin, Gemtuzumab, Alemtuzumab, Ibritumomab, Cetuksimab, Bevacizumab, Tositumomab, Pavlizumab, Infliksimab, Ekulizumab, Epratuzumab, Omalizumab, Efalizumab, Adalimumab, OKT3, protutijelo KM2160 protiv receptora 4 kemokina CC, i protutijelo chCE7 protiv neuroblastoma.
With regard to PMMA, substantial difference is known to exist between the various types of commercially available PMMA slabs. A first type is the extruded slab, obtained from non-crosslinked PMMA, either standard or high impact (HIPMMA), and representing about 60% of the quantity currently available, the remainder being represented by crosslinked PMMA slabs. 
S obzirom na PMMA, poznato je da postoji bitna razlika između različitih vrsta komercijalno raspoloživih PMMA ploča, Prva vrsta je ekstrudirana ploča, koja se dobiva od neumreženog PMMA, bilo da je standardni ili visoko sabijeni PMMA, i predstavlja oko 60 % količine koja je danas raspoloživa, dok ostatak predstavljaju umrežene PMMA ploče.
The composition according to claim 1, wherein said composition is a delayed release composition. 
Sastav u skladu s patentnim zahtjevom 1, pri čemu je navedeni sastav sastav odgođenog oslobađanja.
The process of claim 1, wherein in said indirect heat exchange the aqueous urea stream is concentrated by heat-induced evaporation. 
Postupak prema zahtjevu 1, pri čemu se neizravna izmjena topline koristi za dobivanje koncentrata vodenog mlaza uree pomoću isparavanja potaknutog toplinom.
parallel to the longitudinal direction (L) relative to a vertical level, mirror-symmetrically relative to a horizontal level or both; 
načinjena paralelno u odnosu na uzdužni smjer (L) u odnosu na okomitu ravninu i/ili zrcalno simetrično u odnosu na vodoravnu ravninu; i/ili
The block of wood 12 still being hot was then sliced in a cutting/slicing device for veneers to veneers 14 having a thickness of 0.65 mm (in longitudinal direction perpendicular to the adhesion plane), whereupon the so obtained veneers 14 are dried in a drying equipment at a temperature of 140 °C to a relative wood humidity of approximately 8 %. 
Ovaj blok od drva 12, još dok je bio vruć, bio je rezan na kriške u uređaju za rezanje/rezanje na kriške za dobivanje furnira 14 koji ima debljinu od 0.65 mm (u uzdužnom smjeru okomito na ravninu lijepljenja), nakon čega su tako dobiveni furniri 14 sušeni u opremi za sušenje kod temperature od 140%C do relativne vlažnosti od približno 8 %.
Post IMAC IL-18BP, resulting from step (a), was supplemented with 1M NaCl under stirring up to a conductivity is 95 ± 5 mS/cm. 
IL-18BP dobiven nakon koraka (a) bio je pomiješan s IM NaCI uz miješanje sve dok nije postignuta provodljivost od 95 +5 mS/em.
The method of claim 1, wherein the human patient has not received glatiramer acetate therapy prior to initiation of the treatment. The method of claim 2, wherein the human patient has not received glatiramer acetate therapy prior to initiation of the treatment. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
panthenol of the following formula: and 
pantenol sljedeće formule:
It was then concentrated to remove excess THF; fresh catalyst (101 g) was added and the reaction mixture was placed back under hydrogen as before. 
Tada je bila koncentrirana da bi se uklonio višak THF; bio je dodan svježi katalizator (101 g) i reakcijska smjesa je bila stavljena natrag pod vodik kao i prije.
Use of a compound according to any one of claims 1 to 12, or of a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention and/or treatment of diseases selected from the group consisting of both chronic and acute allergic diseases or immune disorders comprising allergic asthma, rhinitis, chronic obstructive pulmonary disease, dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, systemic mast cell disorders, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, and eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, and basophil-related diseases, such as basophilic leukemia and basophilic leukocytosis. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 12, ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju farmaceutskog sastava za prevenciju i/ili liječenje bolesti odabranih iz skupine koja sadrži bilo kronične bilo akutne alergijske bolesti ili poremećaje imuniteta koji se sastoje od alergijske astme, rinitisa, kronične opstrukcijske plućne bolesti, dermatitisa, upalne bolesti crijeva, reumatoidnog artritisa, alergijskog nefritisa, HR P20110773 TI konjunktivitisa, atopičnog dermatitisa, bronhijalne astme, alergije na hranu, sistemskog staničnog mastičnog poremećaja, anafilaktičkog šoka, urtikarije, ekcema, svraba, upale, ishemijske-reperfuzijske ozljede, cerebrovaskularnih poremećaja, pleuritisa, ulcerativnog kolitisa, i bolesti povezane s eozinofilom, kao što su Churg-Strauss-ov sindrom i sinusitis, te bolesti povezane s bazofilom, kao što su bazofilna leukemija i bazofilna leukocitoza.
The pharmaceutical composition according to claim 1, wherein Form I is characterized as a crystal form having a monoclinic crystal system, a P21/n space group, and the following unit cell dimensions: a = 4.9626 (7) Å 
dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2il)benzoeve kiseline prema zahtjevu 1 koji ima monoklinski kristalni sustav, P2,/n prostornu grupu, i sljedeće dimenzije elementarnih stanica: Deda wmaonR
The jack system of claim 1, comprising three or more spaced apart jacks laterally facing each other, with pipes or cable racks to be selectively raised and lowered, spaced therebetween. 
Sustav dizalica (10, 100) sukladno zahtjevu 2, sastojeći se od tri ili više razmaknutih dizalica (50,150) lateralno okrenutih jedna prema drugoj, s cijevima ili policama za kablove (12,112) koje se selektivno podižu i spuštaju, razmaknutim između njih.
• a case; said at least one pushbutton for manual calls is accessible to the user; said GSM/GPRS communication means being designed to communicate with a purposely provided operating centre designed to provide the rescue service and/or sending of useful information; wherein the rescue call starts with sending of data comprising information regarding the vehicle, its position and the data characterizing the accident, after which the communication passes onto the audio channel; the device being characterised in that it is an all-inclusive device; wherein said GSM/ GPRS communication means and corresponding antenna, means for receiving the signals of the GPS system and corresponding antenna, three-axial crash sensor, hands-free communication means, loudspeaker, microphone, at least one push-button and electronic components being all accommodated into said case; said case is provided with self-adhesive fastening means for enabling installation thereof in a convenient and stable position on the windscreen. 
kućište; korisnik ima na raspolaganju navedenu najmanje jednu tipku za ručne pozive; navedeno sredstvo za GSM/GPRS komunikaciju je dizajnirano za komuniciranje s odgovarajućim operativnim centrom za pružanje usluge spašavanja i/ili slanja korisnih informacija; gdje poziv za spašavanje počinje slanjem podataka koji sadrže informacije o vozilu, njegovom položaju i podataka koji opisuju nesreću, nakon čega komunikacija prelazi na audio kanal; naznačen time što je uređaj sveobuhvatni uređaj; gdje je sve od navedenog sredstva za GSM/GPRS komunikaciju i odgovarajuće antene, sredstva za prijem signala iz GPS sustava i odgovarajuće antene, troosnog osjetila sudara, sredstva za komunikaciju bez upotrebe ruku, zvučnika, mikrofona, najmanje jedne tipke i elektronskih komponenti smješteno u navedeno kućište; gdje navedeno kućište ima samoljepivo sredstvo za pričvršćivanje, koje omogućuje njegovu ugradnju u pogodnom i stabilnom položaju na vjetrobranu.
A method according to claim 1, wherein the disentanglement process comprises feeding the web from a duct with a lower relative air flow to a duct with a higher relative air flow. 
Postupak sukladno patentnom zahtjevu 1, pri čemu taj postupak rasplitanja sadrži dovod mreže iz kanala s nižim relativnim protokom zraka do kanala s višim relativnim protokom zraka.
CHO.K1-CRTh2 cultured in tissue culture flasks are washed with PBS and harvested with dissociation buffer. 
CHO.K1-CRTh2 uzgojene u tikvicama za kulturu tkiva su isprane s PBS-om i skupljene su s puferom za disocijaciju.
The fluid inlet and outlet connectors 154, 156 preferably include normally closed valves (not shown) which prevent fluid flow therethrough when closed, and are opened when the connectors are interconnected with their associated mating connectors to permit fluid flow into and out of the housing 20. 
Ulaz i izlaz za tekućine po mogućnosti imaju i ventile (nisu prikazani), u normalnom radu zatvorene, koji sprečavaju prolaz tekućine kad su zatvoreni, a otvaraju se kad se prespajaju priključci na svoje odgovarajuće spojeve kako bi se dolila ili izlila tekućina iz kućišta (20).
and wherein the recombinant antibody molecule or the a4-binding fragment thereof binds VLA-4. 
(b) kultiviranje stanice za proizvodnju rekombinantne molekule protutijela anti-a4 ili njezinog fragmenta koji veže od.
In a further preferred embodiment of the integrated rotary mixer and disperser head according to the invention the trailing portion of each of said second plurality of impeller blades is integral with and forming an obtuse angle with said leading portion of each of said second impeller blades and in a plane projection having the shape of a sector of an annulus. 
Integrirana rotacijska miješalica 1 glava raspršivača (1) prema 6. tvrdnji gdje je prateći dio (14) svake od navedenog drugog mnoštva lopatica rotora (12) sastavni dio navedenog prednjeg dijela svake od navedenih drugih lopatica rotora (12) i s njim oblikuje tupi kut te u prikazu ravnine ima oblik sektora anulusa.
The thus obtained antibody which neutralizes the biological activity of Siglec-15 is useful as a medicine, particularly as a pharmaceutical composition for treating or preventing abnormal bone metabolism such as osteoporosis, bone destruction accompanying rheumatoid arthritis or bone destruction accompanying cancer metastasis to bone, or as an antibody for immunological diagnosis of such a disease. 
Antitijelo ili njegov funkcionalni fragment za uporabu u skladu sa zahtjevom 21 ili 22, uporaba u skladu sa zahtjevom 23 ili 24, ili preparati za uporabu u skladu sa zahtjevom 25 ili 26, karakterizirani time da je abnormalni metabolizam kostiju osteoporoza, destrukcija kostiju koja prati reumatoidni artritis ili destrukcija kostiju koja prati metastaze raka u kostima.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
The apparatus according to one of Claims 1 to 11, characterized in that the first insulator comprises an anaerobic working fermenter. 
Uređaj prema jednom od Zahtjeva 1 do 11, naznačen time da prvi izolator sadržava anaerobni radni fermentor.
This reduces the number of possible pairings of cysteine residues (and thus intramolecular disulfide bridges) from three to one [46], and improves the outcome of protein re-folding and storage stability. 
Ovo smanjuje broj mogućih sparivanja cisteinskih ostataka (i na taj način intramolekularnih disulfidnih veza) od tri do jedne [46] i poboljšava ishod proteinskog prematanja i stabilnost spremanja.
represents Ar3, Ar4-C1-4alkyl, C1-4alkyl, C2-6alkenyl optionally substituted with Het12 or R17 represents C1-4alkyl substituted with one or where possible two or more substituents selected from C1-4alkyloxy, hydroxy, halo, Het2, NR7R8, NR9R10-carbonyl or Het3-carbonyl; 
predstavlja Ar3, Ar4-C1-4alkil, C1-4alkil, C2-6alkenil proizvoljno supstituiran sa Het12 ili R23 predstavlja C1-4alkil supstituiran sa jednim ili gdje je moguće sa dva ili više supstituenata koji su odabrani iz skupine koja sadrži C1-4alkiloksi, hidroksi, halo, Het2, NR7R8, NR9R10-karbonil ili Het3-karbonil;
Pharmaceutical composition comprising sucralfate as active principle for the treatment of gastrointestinal irritation disorders such as gastric ulcers, duodenal ulcers, acute gastritis, symptomatic chronic gastritis, gastropathy related to anti-inflammatories, reflux esophagitis, characterized by comprising one or more phospholipids. 
Farmaceutska smjesa koja sadrži sukralfat kao djelatnu tvar za liječenje iritabilnih probavnih poremećaja kao što je čir na želucu, čir na dvanaesniku, akutni gastritis, simptomatski kronični gastritis, gastropatija povezana s protuupalnim lijekovima, rTefluksni ezofagitis, naznačena time što sadrži jedan ili više fosfolipida.
to 300 mM sugar stabiliser, wherein the sugar stabiliser is a non-reducing disaccharide selected from the group including trehalose and sucrose; and 
(c) 150 do 300 mM stabilizatora šećera, pri čemu je stabilizator šećera nereducirajući disaharid odabran iz skupine koja sadrži trehalozu i saharozu; i
The dispersion of MPL consists of the following steps: 
Datum objave europske prijave patenta:
send a null data packet 35 to the remaining modulators, e.g., to the at least one second modulator 6 . 
- poslati nulti paket (35) podataka preostalim modulatorima (6).
A kit as defined in claim 1 to 3 wherein, if the second member of the binding pair is coupled to an enzyme tag, then the kit further comprises a substrate which can be converted by said enzyme into a detectable product. 
Komplet u skladu s patentnim zahtjevom 1 do 3 naznačen time što ako je drugi član vežućeg para konjugiran s enzimskim biljegom, komplet dodatno sadrži supstrat kojeg navedeni enzim može prevesti u detektabilni produkt.
where n=8 to 12, and where Z is selected from the group of organic salts, such as citrate, acetate, lactate, tartarate, oxalate, ascorbate, mesylate, tosylate or inorganic salts, such as e.g. sulphate, halogenide, phosphate, and wherein the crossed double bond in the general formula I, situated in the TAX moiety, indicates that the double bond may have E and/or Z configuration, and alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA where n=6 to 10, and where Z has the meaning stated above, and wherein the crossed double bond in the general formula IA, situated in the side chain indicates that the double bond may have E and/or Z configuration. 
I, gdje n = 8 do 12, 1 gdje Z uzeto iz grupe organskih soli, kao što je citrat, acetat, laktat, tartarat, oksalat, askorbat, mesilat, tosilat ili anorganskih soli, kao primjerice sulfat, halogenid, fosfatt i prekrižena dupla veza u općoj formuli I, koja se nalazi u podjedinici tamoksifena uključuje raspored dvostruke veze u konfiguraciji E i/ili Z A alkenil trifenil fosfonijski derivati imaju opću formulu IA, gdje n = 6 do 10, 1 gdje Z ima ispred navedeno značenje i prekrižena dupla veza u općoj formuli IA, koja se nalazi u alkenil lancu uključuje raspored dvostruke veze u konfiguraciji E i/ili Z.
The use of Claim 10, wherein said metal chelator is clioquinol. 
Primjena Zahtjeva 10, naznačena time da navedeni metalni kelat pripada skupini kliokinola.
and they were placed later dorsally on a heated (37°C) surgical board. 
i polegnuti su na leđa na zagrijanu (37*C) kiruršku ploču.
is an unsubstituted C2-10 aliphatic, a substituted C1-10 aliphatic, or an optionally substituted aryl, heteroaryl, or heterocyclyl; 
je nesupstituirana C2-10 alifatična, supstituirana C1-10 alifatična ili izborno supstituirana aril, heteroaril ili heterociklil grupa;
A tablet comprising a first layer and a second layer wherein; a) the first layer comprises rilpivirine HCl and is substantially free of tenofovir disoproxil fumarate, and wherein less than about 12.2 weight percent of the first layer is rilpivirine HCl; b) the second layer comprises tenofovir disoproxil fumarate and is substantially free of rilpivirine HCl; and c) the tablet further comprises emtricitabine. 
HR P20140946 T1 PATENTNI ZAHTJEVI mana» Tableta koja sadrži prvi sloj 1 drugi sloj pri čemu; a) prvi sloj sadrži rilpivirim HCI i suštinski je bez tenofovir dizoproksil fumarata, i pri čemu manje od oko 12.2 masenog postotka prvog sloja je rilpivirin HCI; b) drugi sloj sadrži tenofovir dizoproksil fumarat, i i suštinski je bez rilpivirin HCI; i c) tableta dalje sadrži emtricitabin.
This material is contaminated with about 15% of an identified impurity whose M+1=295. 
Ovaj materijal je zagađen sa oko 15% identificiranih nečistoća čiji je M+1 = 295.
The inventive composition preferably has the form of a liquid, a paste, a bar, a cake, a powder, a granulate, an effervescent tablet, a chewing gum, a tablet, a capsule, a lozenge, a fast melting tablet or wafer, a sublingual tablet or a spray. 
Uporaba u skladu s patentnim zahtjevom 3, pri čemu je navedeni sastav u obliku tekućine, paste, pločice, kolača, praha, granulata, šumeće tablete, tablete, kapsule, dražeje, gume za žvakanje, tablete koja se brzo topi ili vafla, sublingvalne tablete ili spreja.
Preferably, the biologically degradable composite material can be characterised in that the inorganic component (a), (b) and, if present, (d) is a granular material the primary particles of which have a d50 value of at least 10 um. 
Biološki razgradivi kompozitni materijal u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je anorganska komponenta (a), (b) ako je prisutna, (d) granulirani materijal čije primarne čestice imaju vrijednost d50 od najmanje 10 um.
time-deinterleaving the service data symbols at a level of the data slice, the service data symbols are divided into at least one data slices; 
Metoda u skladu s patentnim zahtjevom 1, nadalje obuhvaća: nasumično kodiranje servisnih podataka koji imaju najmanje jedno zaglavlje osnovnog frekvencijskog pojasa.
Device according to claim 9, characterised in that said containment portion (112) and said grip portion (114) are manufactured in a single piece of non-stick material. 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što se navedeni dio za držanje (112) i navedeni dio za hvatanje (114) proizvode u jednom komadu neljepljivog materijala.
The deep brown mixture was then stirred at room temperature overnight. 
Potom se tamno smeđa smjesa miješa preko noći pri sobnoj temperaturi.
The system of the invention therefore allows the yacht to be controlled manually, in a conventional manner, i.e. by operating the levers that actuate the electronic controls, as well as by remote control through use of the hand-held unit. 
Sustav izuma prema tome dopušta da se jahtom upravlja ručno, na konvencionalni način, to jest upravljanjem poluga koje pokreću elektronske kontrole, kao i pomoću daljinskog upravljača korištenjem ručne jedinice.
High Five cells (Invitrogen) was grown at 27°C in suspension to a density of 1*106 and infected with a MOI of 0.5. 
Visoke Pet stanice (Invitrogen) rastu na 27 "C u suspenziji do gustoće 1*10* i inficiraju se sa MOI od 0.5.
The method according to claim 1, wherein the raw meal mixture additionally contains sources for Al2O3 and Fe2O3. 
Postupak sukladno zahtjevu 1, naznačen time što sirova mješavina dodatno sadrži izvore AbO, i Fe,O».
A pharmaceutical unit dosage form suitable for parenteral administration to a human, comprising a formulation according to any of aspects 1 to 67, 69 and/or 71 in a suitable container. 
Farmaceutski jedinični oblik doziranja pogodan za parenteralnu primjenu kod čovjeka, naznačen time što sadrži formulaciju prema bilo kojem od zahtjeva 1 do 15 u pogodnom spremniku. HR P20190137 T1
R2' is selected from the group consisting of optionally substituted aliphatic, optionally substituted aryl, and optionally substituted heteroaryl; or R2' and R7 are taken together with their intervening atoms to form an optionally substituted, carbocyclic or heterocyclic, fused ring; wherein aryl has 6 to 14 ring carbon atoms; and wherein heteroaryl is 5- to 10-membered, and monocyclic or bicyclic, and has 1 to 4 ring heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur; 
' je odabran iz skupine koju čine po izboru supstituiran alifatski, po izboru supstituiran aril, i po izboru supstituiran heteroaril; ili R2' i R7 se uzimaju zajedno s njihovim među atomima tako da tvore po izboru supstituiran, karbociklički ili heterociklički, kondenzirani prsten; pri čemu aril ima 6 do 14 ugljikovih atoma u prstenu; i pri čemu je heteroaril 5- do 10-člani, i monociklički ili biciklički, te ima 1 do 4 heteroatoma prstena neovisno odabranih iz skupine koju čine dušik, kisik, i sumpor;
The increased downwards force can be applied manually or by increasing the pressure in the pressure chamber. 
Povećanu silu prema dolje može se primijeniti ručno ili povećanjem pritiska u tlačnoj komori.